Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Abbott’s Q4 2018 Revenue Misses Estimate, Forecasts Lackluster Q1 2019 Profit

Abbott’s fourth-quarter 2018 revenue fell short of Wall Street expectations due to lower sales of generic drugs in emerging markets as well as a strong dollar, and the healthcare company forecast first-quarter 2019 earnings below analysts’ estimates.

Read More »

Indivior slashes 2018 revenue outlook for Sublocade

Indivior Plc slashed full-year 2018 revenue expectation for the injectable opioid addiction drug Sublocade, sending the company’s shares tumbling more than 16 percent.

Read More »

Roche Q2 2018 Financials: “Firing on All Cylinders”

Switzerland-based Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of 2018 and a 20 percent increase in its core EPS.

Read More »

Abbott Labs tops Q2 2018 profit estimates

Abbott Laboratories raised its 2018 full-year earnings forecast and reported a quarterly profit that beat analysts’ estimates, powered by higher sales across its businesses.

Read More »

Gilead fourth-quarter hepatitis C drug sales plummet, sees further slowdown

Gilead Sciences Inc. said fourth-quarter 2017 sales of its flagship hepatitis C drugs fell by more than half amid increased competition, and the company forecast a further slowdown for 2018.

Read More »

Allergan’s migraine drug succeeds in key study

Allergan Plc reported better-than-expected fourth-quarter 2017 profit and announced positive data on one of the two migraine treatments it is developing.

Read More »

Novo Nordisk warns of U.S. legislation

Drugmaker Novo Nordisk warned that draft legislation in some U.S. states to make pricing more transparent could impact business in the company’s largest market.

Read More »

Pfizer beats Q3 2017 profit estimates

Pfizer Inc.’s third-quarter profit beat market estimates and the company raised its full-year 2017 earnings forecast.

Read More »

New cancer drugs help J&J top profit estimates

Johnson & Johnson reported a higher-than-expected third-quarter 2017 profit and raised its full-year forecast as the company gained from strong sales of its new cancer drugs.

Read More »

Medtronic misses revenue estimates, shares dip

Medical device maker Medtronic Plc reported Q1 fiscal 2018 revenue fell short of analysts’ estimates, hurt by lower sales in its diabetes-related device business.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom